Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Contrast Enhanced Digital Mammography for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy

NCT06220214 is registered in ClinicalTrials.gov with Alison Stopeck as lead sponsor.

NCT NCT06220214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06220214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Contrast Enhanced Digital Mammography for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy
Lead sponsor
Alison Stopeck
Phase
Phase 1
Overall status
Recruiting
Start date
March 6, 2024
Completion date
August 31, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-positive breast cancer, locally advanced breast cancer, neoadjuvant chemotherapy, tnbc, triple negative breast cancer, triple negative breast cancer